Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Some Thoughts in Summary
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2261)
•••
Comment by Boomskidon Dec 23, 2022 4:18pm
136 Views
Post# 35190402

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Some Thoughts in Summary

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Some Thoughts in SummaryMaterial Transfer Agreements with J&J and the others are secret, pof. They generate no revenue until they result in a deal being executed, and they have never helped the Bioasis share price.

Don't tout them as reasons for celebration. Any of them that might turn into business deals with revenue are timed to happen for Biodexa, not for Bioasis.

And the market is saying the deal and all the little deals within it are collectively worth less than 4¢.

Pof, you can't tout this with any meaning to anybody. The best tout you can make is that you hope that the interests of LT and The Placees align with the interests of the original Bioasis and Midatech shareholders.

And I've expressed my concerns about that being the case. 

And xB3-001 being too expensive is bullroar. xB3-001 was being touted as sold to Ellipses until the secret was accidently revealed. What do you think, that the Ellipses presentation wrote itself?

Everything means something.

JD Boomskid
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities